Future strategies may include rational combination therapies integrating KSR1 inhibition with RAF, MEK, or ERK inhibitors to enhance antitumor efficacy and overcome adaptive resistance in HCC and other RAS/MAPK-driven malignancies. Here, MAP2K7 is linked to hepatocellular carcinoma.